Consultation with Dr Peter Pappenhausen at ESI genetic labs.
1.
Villas BH. Flow cytometry: An overview. Cell Vis. 1998; 5(1):56-61.
2.
Gilman-Sachs A. Flow cytometry. Anal Chem. 1994; 66(13):700A-707A.
3.
Martinez JE, Beck JR, Allsbrook WC Jr., et al. Flow cytometric DNA analysis.
Clin Lab Sci. 1990; 3(3):180-183.
4.
Rew DA. Clinical applications of flow cytometry. Br J Hosp. Med. 1992;
48(3-4):171-175.
5.
Byers CD. Clinical applications of flow cytometry. Clin Lab Sci. 1993;
6(3):174-176.
6.
Jennings CD, Foon KA. Recent advances in flow cytometry: Application to the
diagnosis of hematologic malignancy. Blood. 1997; 90(8):2863-2892.
7.
Camplejohn RS. Flow cytometry. J Pathol. 1992; 166(3):323-326.
8.
Johnson KL. Basics of flow cytometry. Clin Lab Sci. 1992; 5(1):22-24.
9.
Goetzman EA. Flow cytometry: Basic concepts and clinical applications in
immunodiagnostics. Clin Lab Sci. 1993; 6(3):177-182.
10.
Bauer KD, Bagwell CB, Giaretti W, et al. Consensus review of the clinical
utility of DNA flow cytometry in colorectal cancer. Cytometry. 1993;
14:486-491.
11.
Albe X, Vassilakos P, Helfer-Guarnori K, et al. Independent prognostic value
of ploidy in colorectal cancer: A prospective study using image cytometry.
Cancer. 1990; 66:1168-1175.
12.
Tomoda H, Kakeji Y, Furusawa M. Prognostic significance of flow cytometric
analysis of DNA content in colorectal cancer: A prospective study. J Surg Onc.
1993; 53:144-148.
13.
Silvestrini R, D`Agnano I, Faranda A, et al. Flow cytometric analysis of
ploidy in colorectal cancer: A multicentric experience. Br J Cancer. 1993;
67:1042-1046.
14.
Winchester DP. Standards for diagnosis and management of invasive breast
carcinoma. American College of Radiology. American College of Surgeons. College
of American Pathologists. Society of Surgical Oncology. CA Cancer J Clin. 1998;
48(2):83-107.
15.
Hedley D. DNA flow cytometry and breast cancer. Breast Cancer Res Treat.
1993; 28:51-53.
16.
Pisani T, De Iorio P, Cenci M, et al. Evaluation of cellular proliferative
activity and DNA ploidy as a prognostic factor in breast cancer. Minerva
Ginecol. 1999; 51(1-2):1-5.
17.
Lage JM, Weinberg DS, Huettner PC, et al. Flow cytometric analysis of
nuclear DNA content in ovarian tumors: Association of ploidy with tumor type,
histologic grade, and clinical stage. Cancer. 1992; 69(11)2668-2675.
18.
Trope C, Kaern J. DNA ploidy in epithelial ovarian cancer: A new independent
prognostic factor? Gynecol Oncol. 1994; 53:1-4. Editorial.
19.
Currin SM, Lee SE, Walther PJ. Flow cytometric assessment of
deoxyribonucleic acid content in renal adenocarcinoma: Does ploidy status
enhance prognostic stratification over stage alone? J Urol. 1990; 143:458-463.
20.
Jackson JF, Boyett J, Pullen J, et al. Favorable prognosis associated with
hyperdiploidy in children with acute lymphocytic leukemia correlates with extra
chromosome 6: A Pediatric Oncology Group study. Cancer. 1990; 66(6):1183-1189.
21.
Nativ O, Winkler HZ, and Raz Y, et al. Stage C prostatic adenocarcinoma:
Flow cytometric nuclear DNA ploidy analysis. Mayo Clinic Proc. 1989;
64(8):911-919.
22.
Lee SE, Currin SM, Paulson DF, et al. Flow cytometric determination of
ploidy in prostatic adenocarcinoma: A comparison with seminal vesicle
involvement and histopathological grading as a predictor of clinical recurrence.
J Urol. 1988; 140(4):769-774.
23.
Ritchie AW, Dorey F, Layfield LJ, et al. Relationship of DNA content to
conventional prognostic factors in clinically localized carcinoma of the
prostate. B J Urol. 1988; 62(3):254-260.
24.
Shearer WT, Buckley RH, Engler RJM, et al. Practice parameters for the
diagnosis and management of immunodeficiency. Ann Allergy Asthma Immunol. 1996;
76(3):282-294.
25.
Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for
the use of tumor markers in breast and colorectal cancer: Clinical practice
guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;
19(6):1865-1878.
26.
Huang HY, Sung MT, Eng. HL, et al. Solitary fibrous tumor of the abdominal
wall: A report of two cases immunohistochemical, flow cytometric, and
ultrastructural studies and literature review. APMIS. 2002; 110(3):253-262.
27.
Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in
node-negative breast cancer: A review of studies with sample size more than 200
and follow-up more than 5 years. Ann Surg. 2002; 235(1):10-26.
28.
Ottesen GL. Carcinoma in situ of the female breast. A clinico-pathological,
immunohistological, and DNA ploidy study. APMIS Suppl. 2003 ;( 108):1-67.
29.
Eissa S, Kassim S, El-Ahmady O. Detection of bladder tumors: Role of
cytology, morphology-based assays, biochemical and molecular markers. Curr Opin
Obstet Gynecol. 2003; 15(5):395-403.
30.
National Health and Medical Research Council (NHMRC). Clinical Practice
Guidelines: The management of cutaneous melanoma. A report of the Australian
Cancer Network Working Party on Cutaneous Melanoma. Canberra, ACT: AusInfo
Government Info; December 1999.
31.
Shelley W, Trudeau M; Breast Cancer Disease Site Group. Adjuvant systemic
therapy for node-negative breast cancer. Practice Guideline Report #1-8. Cancer
Care Ontario Program in Evidence-Based Care. Toronto, ON: Cancer Care Ontario;
February 2002.
32.
National Health and Medical Research Council (NHMRC). Clinical Practice
Guidelines: Evidence-based information and recommendations for the management of
localized prostate cancer. A report of the Australian Cancer Network Working
Party on Management of Localized Prostate Cancer. Canberra, ACT: AusInfo
Government Info; 2003.
33.
Otchy D, Hyman NH, Simmang C, et al. Practice parameters for colon cancer.
Dis Colon Rectum. 2004; 47(8):1269-1284.
34.
Royal College of Obstetricians and Gynecologists (RCOG). The management of
gestational trophoblastic neoplasia. Guideline No. 38. London, UK: RCOG;
February 2004.
35.
Elit L, Fyles A, Chambers A, et al.; Gynecology Cancer Disease Site Group.
Adjuvant care for stage I ovarian cancer. Practice Guideline Report #4-13.
Cancer Care Ontario Program in Evidence-Based Care. Toronto, ON: Cancer Care
Ontario; May 3, 2004.
36.
Habermehl P, Knuf M, Schwarz M, et al. Flow-cytometric DNA analysis of
intracranial tumors in children. Pathol Res Pract. 2004; 200(3):197-202.
37.
Mesiwala AH, Scampavia LD, Rabinovitch PS, On-line flow cytometry for
real-time surgical guidance. Neurosurgery. 2004; 55(3):551-560; discussion
560-561.
38.
Russo A, Bazan V, Migliavacca M, et al. DNA aneuploidy and high
proliferative activity but not K-ras-2 mutations as independent predictors of
clinical outcome in operable gastric carcinoma: Results of a 5-year Gruppo
Oncologico dell`Italia Meridonale (GDIM) prospective study. Cancer. 2001;
92(2):294-302.
39.
Jiao YF, Sugai T, Suzuki M, et al. Application of the crypt isolation
technique to the flow cytometric analysis of DNA content in gastric carcinoma.
Hum Pathol. 2004; 35(5):587-593.
40.
Royal College of Obstetricians and Gynecologists (RCOG). The management of
gestational trophoblastic neoplasia. London, UK: RCOG; February 2004.
41.
Milligan DW, Grimwade D, Cullis JO, et al. Guidelines on the management of
acute myeloid leukemia in adults. London, UK: British Society of Hematology
(BSH); May 23, 2005.
42.
Smith A, Wisloff F, Samson D; UK Myeloma Forum, Nordic Myeloma Study Group,
British Committee for Standards in Hematology. Guidelines on the diagnosis and
management of multiple myeloma 2005. Br J Haematol. 2006; 132(4):410-451.
43.
Yasa MH, Bektas A, Yukselen V, et al. DNA analysis and DNA ploidy in gastric
cancer and gastric precancerous lesions. Int J Clin Pract. 2005;
59(9):1029-1033.
44.
Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations
for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;
24(33):5313-5327.
45.
Harris L, Fritsche H, Mennel R, et al; American Society of Clinical
Oncology. American Society of Clinical Oncology 2007 update of recommendations
for the use of tumor markers in breast cancer. J Clin Oncol. 2007;
25(33):5287-5312.
46.
Araujo SE, Bernardo WM, Habr-Gama A, et al. DNA ploidy status and prognosis
in colorectal cancer: A meta-analysis of published data. Dis Colon Rectum. 2007;
50(11):1800-1810.
47.
Wolfson AH, Winter K, Crook W, et al. Are increased tumor aneuploidy and
heightened cell proliferation along with heterogeneity associated with patient
outcome for carcinomas of the uterine cervix? A combined analysis of subjects
treated in RTOG 9001 and a single-institution trial. Int J Radiat Oncol Biol
Phys. 2008; 70(1):111-117.
48.
Suehiro Y, Okada T, Okada T, et al. Aneuploidy predicts outcome in patients
with endometrial carcinoma and is related to lack of CDH13 hyper methylation.
Clin Cancer Res. 2008; 14(11):3354-3361.
49.
Dabic MM, Nola M, Tomicic I, et al. Adenocarcinoma of the uterine cervix:
Prognostic significance of clinic pathologic parameters, flow cytometry analysis
and HPV infection. Acta Obstet Gynecol Scand. 2008; 87(3):366-372.
50.
Ludovini V, Pistola L, Gregorc V, et al. Biological markers and DNA flow
cytometric analysis in radically resected patients with non-small cell lung
cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
Tumori. 2008; 94(3):398-405.
51.
Sutcliffe P, Hummel S, Simpson E, et al. Use of classical and novel
biomarkers as prognostic risk factors for localized prostate cancer: A
systematic review. Health Technol Assess. 2009; 13(5):1-242.
52.
Alberta Provincial Hematology Tumour Team. Lymphoma. Clinical Practice
Guideline No. LYHE-002. Edmonton, AB: Alberta Health Services, Cancer Care;
September 2012.
53.
No authors listed. Statement on sarcoidosis. Joint Statement of the American
Thoracic Society (ATS), the European Respiratory Society (ERS) and the World
Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by
the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am
J Respir Crit Care Med. 1999; 160(2):736-755. Available at:
http://www.thoracic.org/statements/resources/interstitial-lung-disease/sarcoid1-20.pdf.
Accessed February 19, 2015.
54.
Zhang Z, Weaver DL, Munjal K, Evans MF. Intratumoral DNA content
heterogeneity in breast carcinomas demonstrated by core punch tissue sampling
and flow cytometry. J Clin Pathol. 2014; 67(9):821-824.
55.
King TE Jr. Clinical manifestations and diagnosis of pulmonary sarcoidosis.
Up-to-date Inc., Waltham, MA. Last reviewed January 2015.
56.
Lu Y, Liang H, Yu T, et al. Isolation and characterization of living
circulating tumor cells in patients by immunomagnetic negative enrichment
coupled with flow cytometry. Cancer. 2015; 121(17):3036-3045.
57.
Midthun DE. Overview of the initial evaluation, treatment and prognosis of
lung cancer. Up-to-date Inc., Waltham, MA. Last reviewed January 2016.
58.
National Comprehensive Cancer Network. Clinical practice guideline: Small
cell lung cancer. Version 1.2016. NCCN: Fort Washington, PA.